Seroatlas · Human Serome Atlas

KIF17

Kinesin-like protein KIF17

Also known as: KIAA1405, KIF17_HUMAN, KIF17B, KIF3X, KLP-2, OSM-3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9P2E2
Gene
KIF17
Ensembl
ENSG00000117245
Chromosome
1
Canonical length
1029 aa
Protein class
Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Plasma membrane,Primary cilium tip,Basal body,Cytosol,Acrosome,Principal piece
Quaternary structure
Homodimer

OverviewNCBI Gene

Predicted to enable ATP hydrolysis activity; microtubule binding activity; and plus-end-directed microtubule motor activity. Predicted to be involved in anterograde dendritic transport of neurotransmitter receptor complex and cell projection organization. Predicted to act upstream of or within microtubule-based process; protein-containing complex localization; and vesicle-mediated transport. Predicted to be located in cytosol. Predicted to be part of kinesin complex. Predicted to be active in several cellular components, including cilium; microtubule cytoskeleton; and postsynapse. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

1029 residues, UniProt reviewed canonical sequence.

>Q9P2E2|KIF17
     1  MASEAVKVVV RCRPMNQRER ELRCQPVVTV DCARAQCCIQ NPGAADEPPK QFTFDGAYHV
    61  DHVTEQIYNE IAYPLVEGVT EGYNGTIFAY GQTGSGKSFT MQGLPDPPSQ RGIIPRAFEH
   121  VFESVQCAEN TKFLVRASYL EIYNEDVRDL LGADTKQKLE LKEHPEKGVY VKGLSMHTVH
   181  SVAQCEHIME TGWKNRSVGY TLMNKDSSRS HSIFTISIEM SAVDERGKDH LRAGKLNLVD
   241  LAGSERQSKT GATGERLKEA TKINLSLSAL GNVISALVDG RCKHVPYRDS KLTRLLQDSL
   301  GGNTKTLMVA CLSPADNNYD ETLSTLRYAN RAKNIRNKPR INEDPKDALL REYQEEIKKL
   361  KAILTQQMSP SSLSALLSRQ VPPDPVQVEE KLLPQPVIQH DVEAEKQLIR EEYEERLARL
   421  KADYKAEQES RARLEEDITA MRNSYDVRLS TLEENLRKET EAVLQVGVLY KAEVMSRAEF
   481  ASSAEYPPAF QYETVVKPKV FSTTDTLPSD DVSKTQVSSR FAELPKVEPS KSEISLGSSE
   541  SSSLEETSVS EAFPGPEEPS NVEVSMPTEE SRSRYFLDEC LGQEAAGHLL GEQNYLPQEE
   601  PQEVPLQGLL GLQDPFAEVE AKLARLSSTV ARTDAPQADV PKVPVQVPAP TDLLEPSDAR
   661  PEAEAADDFP PRPEVDLASE VALEVVRTAE PGVWLEAQAP VALVAQPEPL PATAGVKRES
   721  VGMEVAVLTD DPLPVVDQQQ VLARLQLLEQ QVVGGEQAKN KDLKEKHKRR KRYADERRKQ
   781  LVAALQNSDE DSGDWVLLNV YDSIQEEVRA KSKLLEKMQR KLRAAEVEIK DLQSEFQLEK
   841  IDYLATIRRQ ERDSMLLQQL LEQVQPLIRR DCNYSNLEKI LRESCWDEDN GFWKIPHPVI
   901  TKTSLPVAVS TGPQNKPARK TSAADNGEPN MEDDRYRLML SRSNSENIAS NYFRSKRASQ
   961  ILSTDARKSL THHNSPPGLS CPLSNNSAIP PTQAPEMPQP RPFRLESLDI PFTKAKRKKS
  1021  KSNFGSEPL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against KIF17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.5
Highest tissue expression
21 nTPM

Expression across tissuesHPA

Tissue

  • testis: 21 nTPM
  • basal ganglia: 4.3 nTPM
  • cerebral cortex: 3.5 nTPM
  • hypothalamus: 3 nTPM
  • amygdala: 1.9 nTPM
  • fallopian tube: 1.7 nTPM

Single-cell type

  • late spermatids: 164 nCPM
  • early spermatids: 57 nCPM
  • ependymal cells: 42 nCPM
  • late primary spermatocytes: 35 nCPM
  • respiratory ciliated cells: 30 nCPM
  • epididymal efferent duct ciliated cells: 26 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • hypothalamus: 16 nTPM
  • cerebral cortex: 12 nTPM
  • basal ganglia: 10 nTPM
  • choroid plexus: 9.4 nTPM
  • midbrain: 7.9 nTPM
  • amygdala: 7.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.05
gnomAD pLI
0
gnomAD missense Z
0.29
DepMap mean gene effect
-0.06
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of KIF17 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads KIF17 as an antibody target. Whether an autoantibody or antibody against KIF17 could matter depends on whether native KIF17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

KIF17 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label KIF17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/KIF17. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...